{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T16:04:53Z","timestamp":1791821093988,"version":"4.3.4"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2024,12,29]],"date-time":"2024-12-29T00:00:00Z","timestamp":1735430400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,12,29]],"date-time":"2024-12-29T00:00:00Z","timestamp":1735430400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"Institutional Development Award (IDeA) from the NIGMS of the National Institutes of Health","award":["P20GM113226"],"award-info":[{"award-number":["P20GM113226"]}]},{"name":"National Institutes of Health from the R44 Small Business Innovation Research Grant","award":["CA257683-01A1"],"award-info":[{"award-number":["CA257683-01A1"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Surg Oncol"],"published-print":{"date-parts":[[2025,4]]},"DOI":"10.1245\/s10434-024-16742-3","type":"journal-article","created":{"date-parts":[[2024,12,29]],"date-time":"2024-12-29T22:26:43Z","timestamp":1735511203000},"page":"2786-2798","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Enhancing the Immunotherapeutic Effect by IP-001 and Irreversible Electroporation in Mouse Oligometastatic Models of Pancreatic Adenocarcinoma"],"prefix":"10.1245","volume":"32","author":[{"given":"Yan","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samuel S. K.","family":"Lam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yonglin","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emily","family":"Shore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David W.","family":"Anderson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomas","family":"Hode","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert C.","family":"Martin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,12,29]]},"reference":[{"key":"16742_CR1","volume-title":"SEER Cancer Statistic Review, 1975\u20132017","author":"N Howlader","year":"2019","unstructured":"Howlader N, Noone AM, Krapcho M, Miller D, Brest A, Yu M, et al. SEER Cancer Statistic Review, 1975\u20132017. Bethesda, MD: National Cancer Institute; 2019."},{"key":"16742_CR2","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21590","volume":"70","author":"RL Siegel","year":"2020","unstructured":"Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. CA Cancer J Clin. 2020;70:7\u201330.","journal-title":"CA Cancer J Clin."},{"key":"16742_CR3","doi-asserted-by":"publisher","first-page":"1691","DOI":"10.1056\/NEJMoa1304369","volume":"369","author":"DD Von Hoff","year":"2013","unstructured":"Von Hoff DD, Ervin T, Arena FP, Chiorean EG, Infante J, Moore M, et al. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med. 2013;369:1691\u2013703.","journal-title":"N Engl J Med."},{"key":"16742_CR4","doi-asserted-by":"publisher","first-page":"1817","DOI":"10.1056\/NEJMoa1011923","volume":"364","author":"T Conroy","year":"2011","unstructured":"Conroy T, Desseigne F, Ychou M, Bouche O, Guimbaud R, Becouarn Y, et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med. 2011;364:1817\u201325.","journal-title":"N Engl J Med."},{"key":"16742_CR5","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.843769","volume":"12","author":"A Gyftopoulos","year":"2022","unstructured":"Gyftopoulos A, Ziogas IA, Barbas AS, Moris D. The synergistic role of irreversible electroporation and chemotherapy for locally advanced pancreatic cancer. Front Oncol. 2022;12:843769.","journal-title":"Front Oncol."},{"key":"16742_CR6","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1097\/SLA.0000000000001441","volume":"262","author":"RC Martin II","year":"2015","unstructured":"Martin RC II, Kwon D, Chalikonda S, Sellers M, Kotz E, Scoggins C, et al. Treatment of 200 locally advanced (stage III) pancreatic adenocarcinoma patients with irreversible electroporation: safety and efficacy. Ann Surg. 2015;262:486\u201394.","journal-title":"Ann Surg."},{"key":"16742_CR7","doi-asserted-by":"crossref","unstructured":"Graybill PM, Davalos RV. Cytoskeletal disruption after electroporation and its significance to pulsed electric field therapies. Cancers Basel. 2020;12.","DOI":"10.3390\/cancers12051132"},{"key":"16742_CR8","doi-asserted-by":"publisher","DOI":"10.1016\/j.bioelechem.2019.107369","volume":"131","author":"EM Wasson","year":"2020","unstructured":"Wasson EM, Alinezhadbalalami N, Brock RM, Allen IC, Verbridge SS, Davalos RV. Understanding the role of calcium-mediated cell death in high-frequency irreversible electroporation. Bioelectrochemistry. 2020;131:107369.","journal-title":"Bioelectrochemistry."},{"key":"16742_CR9","doi-asserted-by":"publisher","first-page":"800","DOI":"10.1245\/s10434-018-07144-3","volume":"26","author":"H Pandit","year":"2019","unstructured":"Pandit H, Hong YK, Li Y, Rostas J, Pulliam Z, Li SP, et al. Evaluating the regulatory immunomodulation effect of irreversible electroporation (IRE) in pancreatic adenocarcinoma. Ann Surg Oncol. 2019;26:800\u20136.","journal-title":"Ann Surg Oncol."},{"key":"16742_CR10","doi-asserted-by":"publisher","first-page":"17739","DOI":"10.1038\/s41598-019-53974-w","volume":"9","author":"N Beitel-White","year":"2019","unstructured":"Beitel-White N, Martin RCG, Li Y, Brock RM, Allen IC, Davalos RV. Real-time prediction of patient immune cell modulation during irreversible electroporation therapy. Sci Rep. 2019;9:17739.","journal-title":"Sci Rep."},{"key":"16742_CR11","doi-asserted-by":"publisher","first-page":"610","DOI":"10.1016\/j.surg.2020.04.057","volume":"168","author":"C O\u2019Neill","year":"2020","unstructured":"O\u2019Neill C, Hayat T, Hamm J, Healey M, Zheng Q, Li Y, et al. A phase 1b trial of concurrent immunotherapy and irreversible electroporation in the treatment of locally advanced pancreatic adenocarcinoma. Surgery. 2020;168:610\u20136.","journal-title":"Surgery."},{"key":"16742_CR12","doi-asserted-by":"publisher","first-page":"492","DOI":"10.3390\/cells10030492","volume":"10","author":"M Korbelik","year":"2021","unstructured":"Korbelik M, Hode T, Lam SS, Chen WR. Novel immune stimulant amplifies direct tumoricidal effect of cancer ablation therapies and their systemic antitumor immune efficacy. Cells. 2021;10:492.","journal-title":"Cells."},{"key":"16742_CR13","doi-asserted-by":"publisher","first-page":"5335","DOI":"10.1158\/1078-0432.CCR-18-1126","volume":"24","author":"F Zhou","year":"2018","unstructured":"Zhou F, Yang J, Zhang Y, Liu M, Lang ML, Li M, et al. Local phototherapy synergizes with immunoadjuvant for treatment of pancreatic cancer through induced immunogenic tumor vaccine. Clin Cancer Res. 2018;24:5335\u201346.","journal-title":"Clin Cancer Res."},{"key":"16742_CR14","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1177\/1534735410387597","volume":"10","author":"X Li","year":"2011","unstructured":"Li X, Le H, Wolf RF, Chen VA, Sarkar A, Nordquist RE, et al. Long-term effect on EMT6 tumors in mice induced by combination of laser immunotherapy and surgery. Integrative Cancer Ther. 2011;10:368\u201373.","journal-title":"Integrative Cancer Ther."},{"key":"16742_CR15","doi-asserted-by":"publisher","first-page":"1053","DOI":"10.1002\/ijc.11501","volume":"107","author":"WR Chen","year":"2003","unstructured":"Chen WR, Jeong SW, Lucroy MD, Wolf RF, Howard EW, Liu H, et al. Induced antitumor immunity against DMBA-4 metastatic mammary tumors in rats using laser immunotherapy. Int J Cancer. 2003;107:1053\u20137.","journal-title":"Int J Cancer."},{"key":"16742_CR16","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2019.105764","volume":"75","author":"M Korbelik","year":"2019","unstructured":"Korbelik M, Ban\u00e1th J, Zhang W, Gallagher P, Hode T, Lam SS, et al. N-dihydrogalactochitosan as immune and direct antitumor agent amplifying the effects of photodynamic therapy and photodynamic therapy-generated vaccines. Int Immunopharmacol. 2019;75:105764.","journal-title":"Int Immunopharmacol."},{"key":"16742_CR17","first-page":"190","volume":"81","author":"WR Chen","year":"2005","unstructured":"Chen WR, Korbelik M, Battels KE, Liu H, Sun J, Nordquist RE. Enhancement of laser cancer treatment by a chitosan-derived immunoadjuvant. Photochem Photobiol. 2005;81:190\u20135.","journal-title":"Photochem Photobiol."},{"key":"16742_CR18","first-page":"2965","volume":"37","author":"HY Chiu","year":"2017","unstructured":"Chiu HY, Leu JD, Chang CY, Lee YJ, Chen WR. Combination of radiofrequency ablation and glycated chitosan as treatment on a syngeneic breast tumor model. Anticancer Res. 2017;37:2965\u201374.","journal-title":"Anticancer Res."},{"key":"16742_CR19","doi-asserted-by":"publisher","DOI":"10.1038\/cddis.2014.159","volume":"5","author":"Y Chen","year":"2014","unstructured":"Chen Y, Wang C, Yang F, Wang B, Chen J, Lin L, et al. Synergistic effects of glycated chitosan with high-intensity focused ultrasound on suppression of metastases in a syngeneic breast tumor model. Cell Death Dis. 2014;5:e1178.","journal-title":"Cell Death Dis."},{"key":"16742_CR20","doi-asserted-by":"publisher","first-page":"5581","DOI":"10.3390\/ijms20225581","volume":"20","author":"C-Y Wang","year":"2019","unstructured":"Wang C-Y, Chang C-Y, Wang C-Y, Liu K, Kang C-Y, Lee Y-J, et al. N-dihydrogalactochitosan potentiates the radiosensitivity of liver metastatic tumor cells originated from murine breast tumors. Int J Mol Sci. 2019;20:5581.","journal-title":"Int J Mol Sci."},{"key":"16742_CR21","doi-asserted-by":"crossref","unstructured":"Petty AJ, Dai R, Lapalombella R, Baiocchi RA, Benson DM, Li Z, et al. Hedgehog-induced PD-L1 on tumor-associated macrophages is critical for suppression of tumor-infiltrating CD8+ T cell function. JCI Insight. 2021;6.","DOI":"10.1172\/jci.insight.146707"},{"key":"16742_CR22","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1038\/nri.2017.158","volume":"18","author":"S Jung","year":"2018","unstructured":"Jung S. Macrophages and monocytes in 2017: macrophages and monocytes: of tortoises and hares. Nat Rev Immunol. 2018;18:85\u20136.","journal-title":"Nat Rev Immunol."},{"issue":"312\u201325","key":"16742_CR23","volume":"49","author":"CL Scott","year":"2018","unstructured":"Scott CL, T\u2019Jonck W, Martens L, Todorov H, Sichien D, Soen B, et al. The transcription factor ZEB2 is required to maintain the tissue-specific identities of macrophages. Immunity. 2018;49(312\u201325):e5.","journal-title":"Immunity."},{"key":"16742_CR24","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1158\/2159-8290.CD-18-0123","volume":"8","author":"E Riquelme","year":"2018","unstructured":"Riquelme E, Maitra A, McAllister F. Immunotherapy for pancreatic cancer: more than just a gut feeling. Cancer Discov. 2018;8:386\u20138.","journal-title":"Cancer Discov."},{"key":"16742_CR25","doi-asserted-by":"crossref","unstructured":"Pihlak R, Weaver JMJ, Valle JW, McNamara MG. Advances in molecular profiling and categorisation of pancreatic adenocarcinoma and the implications for therapy. Cancers Basel. 2018;10.","DOI":"10.3390\/cancers10010017"},{"key":"16742_CR26","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1038\/s41586-023-06063-y","volume":"618","author":"LA Rojas","year":"2023","unstructured":"Rojas LA, Sethna Z, Soares KC, Olcese C, Pang N, Patterson E, et al. Personalized RNA neoantigen vaccines stimulate T cells in pancreatic cancer. Nature. 2023;618:144\u201350.","journal-title":"Nature."},{"key":"16742_CR27","doi-asserted-by":"crossref","unstructured":"Timmer FEF, Geboers B, Nieuwenhuizen S, Dijkstra M, Schouten EAC, Puijk RS, et al. Pancreatic cancer and immunotherapy: a clinical overview. Cancers Basel. 2021;13.","DOI":"10.3390\/cancers13164138"},{"key":"16742_CR28","doi-asserted-by":"publisher","first-page":"6094","DOI":"10.1158\/1078-0432.CCR-17-0899","volume":"23","author":"MA Lowery","year":"2017","unstructured":"Lowery MA, Jordan EJ, Basturk O, Ptashkin RN, Zehir A, Berger MF, et al. Real-time genomic profiling of pancreatic ductal adenocarcinoma: potential actionability and correlation with clinical phenotype. Clin Cancer Res. 2017;23:6094\u2013100.","journal-title":"Clin Cancer Res."},{"key":"16742_CR29","first-page":"3304","volume":"11","author":"X Shi","year":"2021","unstructured":"Shi X, O\u2019Neill C, Wang X, Chen Y, Yu Y, Tan M, et al. Irreversible electroporation enhances immunotherapeutic effect in the off-target tumor in a murine model of orthotopic HCC. Am J Cancer Res. 2021;11:3304\u201319.","journal-title":"Am J Cancer Res."},{"key":"16742_CR30","first-page":"165","volume":"12","author":"CH O\u2019Neill","year":"2022","unstructured":"O\u2019Neill CH, Tan M, Yan J, Li Y, Martin RCG. Perioperative systemic immunophenotype following irreversible electroporation (IRE) predicts recurrence. Am J Cancer Res. 2022;12:165\u201375.","journal-title":"Am J Cancer Res."}],"container-title":["Annals of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-024-16742-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1245\/s10434-024-16742-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-024-16742-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,5]],"date-time":"2025-03-05T17:28:58Z","timestamp":1741195738000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1245\/s10434-024-16742-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,29]]},"references-count":30,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,4]]}},"alternative-id":["16742"],"URL":"https:\/\/doi.org\/10.1245\/s10434-024-16742-3","relation":{},"ISSN":["1068-9265","1534-4681"],"issn-type":[{"value":"1068-9265","type":"print"},{"value":"1534-4681","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12,29]]},"assertion":[{"value":"28 August 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 December 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 December 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Immunophotonics provided the IP-001 as an unrestricted educational grant. Robert C. Martin is a paid educational consultant for Angiodynamics, a manufacturer of IRE. Samuel S. K. Lam is a full-time employee of Immunophotonics, Inc and one of the authors listed in one of the IPs of IP-001. David Anderson is an employee of Immunophotonics and a shareholder. The remaining authors have no conflicts of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosure"}}]}}